Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

28.47 -1.66 (-5.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 874,161
Open 28.54
Bid (Size) 28.47 (29)
Ask (Size) 28.48 (18)
Prev. Close 30.13
Today's Range 28.00 - 29.39
52wk Range 18.61 - 47.32
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable.
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill

Performance

YTD
-29.6%
-29.6%
1 Month
-15.2%
-15.2%
3 Month
-29.6%
-29.6%
6 Month
-15.8%
-15.8%
1 Year
+38.8%
+38.8%

More News

Read More
5 Analysts Assess Veracyte: What You Need To Know
Via Benzinga
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts
Via Benzinga
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
Via Chartmill
Demystifying Veracyte: Insights From 7 Analyst Reviews
Via Benzinga
Exploring NASDAQ:VCYT's high growth characteristics.
Via Chartmill
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
From Veracyte, Inc.
Via Business Wire
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Via Benzinga
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank.
Via Chartmill
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive
Via Benzinga
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?
Via Chartmill
Navigating 9 Analyst Ratings For Veracyte
Via Benzinga
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies?
Via Chartmill
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For February 24, 2025
Via Benzinga
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
From Veracyte
Via Business Wire
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 28.47
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 04/03/25 04:00 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 1.92B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.